research Vaniqa--eflornithine 13.9% cream.
This study found that eflornithine HCl 13.9% cream reduces unwanted facial hair growth in women, with effects seen in up to 60% of participants over 4-8 weeks, with mostly minor skin irritation reported.
Search
forResearch
5 / 216 resultsresearch Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa™), a Novel Treatment for Excessive Facial Hair
This research reported that eflornithine HCl 13.9% cream generally has a favorable dermal safety profile for managing unwanted facial hair in women, though it can cause mild irritation under certain conditions.
research The evaluation and management of hirsutism*1
This review discusses the diagnosis and treatment of hirsutism, emphasizing that a systematic evaluation can determine its cause, while combination therapy effectively manages the condition for most patients.
research Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
This study found that topical eflornithine HCl 13.9% cream effectively reduced facial hair in women, with a favorable safety profile.
research Methods in hair research: how to objectively distinguish between anagen and catagen in human hair follicle organ culture
This study introduced a new classification system for distinguishing between anagen VI and early catagen stages in human hair follicle organ culture, using it to confirm eflornithine's ability to induce premature catagen.
Learn
— no results
Community Join
— no results
Experts
— no results
Clinics
— no results